ERBB2 and breast carcinoma: In a phase II clinical trial using granulocyte–macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant, it has been reported that GP2 decreased the risk of recurrence in women with HER2/neu breast cancer[37].